D-Mannose Alleviates Type 2 Diabetes and Rescues Multi-Organ Deteriorations by Controlling Release of Pathological Extracellular Vesicles

Abstract

Type 2 diabetes (T2D) is a prevalent metabolic disease inducing alterations of multiple organ systems with currently no cure. Extracellular vesicles (EVs) have been increasingly noticed as one critical paracrine communicator inducing insulin resistance and metabolic disorders in T2D, but clinically available pharmaceuticals for controlling pathological EV release is lacking. Here, we discover that the natural monosaccharide D-mannose exists with an altered level in the db/db mouse T2D model. Intriguingly, oral administration of D-mannose with the drinking water safely ameliorates diabetic symptoms in db/db mice. D-mannose administration does not critically regulate the gut microbiome and circulatory T lymphocytes in treating T2D, while administrated D-mannose rapidly accumulates in the liver, alleviates hepatic steatosis and rescues insulin resistance. Regarding the mechanism, the T2D pathological EVs released by macrophages are targeted and reduced by D-mannose, which metabolically inhibits CD36 expression and restores function of hepatocytes. Importantly, by regulating macrophage EV release, D-mannose administration reveals extra-hepatic benefits and retards diabetic bone loss. Taken together, our findings unveil D-mannose as a candidate T2D therapeutic and highlight sugars governing intercellular EV crosstalk, paving an avenue for pharmaceutical T2D approaches with amelioration of multi-organ deteriorations.

Keywords

D-mannose / type 2 diabetes / fatty liver / macrophage / extracellular vesicles / osteoporosis

References

[1] R. A. DeFronzo, E. Ferrannini, L. Groop, et al., “Type 2 Diabetes Mellitus,” Nature Reviews Disease Primers1 (2015): 15019.

[2] P. Saeedi, I. Petersohn, P. Salpea, et al., “Global and Regional Diabetes Prevalence Estimates for 2019 and Projections for 2030 and 2045: Results From the International Diabetes Federation Diabetes Atlas, 9th Edition,” Diabetes Research and Clinical Practice157 (2019): 107843.

[3] Y. Zheng, S. H. Ley, and F. B. Hu, “Global Aetiology and Epidemiology of Type 2 Diabetes Mellitus and Its Complications,” Nature Reviews Endocrinology14 (2018): 88-98.

[4] A. L. Birkenfeld and G. I. Shulman, “Nonalcoholic Fatty Liver Disease, Hepatic Insulin Resistance, and Type 2 Diabetes,” Hepatology59 (2014): 713-723.

[5] A. Sheu, J. R. Greenfield, C. P. White, and J. R. Center, “Assessment and Treatment of Osteoporosis and Fractures in Type 2 Diabetes,” Trends in Endocrinology and Metabolism33 (2022): 333-344.

[6] J. C. McNelis and J. M. Olefsky, “Macrophages, Immunity, and Metabolic Disease,” Immunity41 (2014): 36-48.

[7] G. Raposo and P. D. Stahl, “Extracellular Vesicles—on the Cusp of a New Language in the Biological Sciences,” Extracellular Vesicles and Circulating Nucleic Acids4 (2023): 240-254.

[8] Z. Zhao, H. Wijerathne, A. K. Godwin, and S. A. Soper, “Isolation and Analysis Methods of Extracellular Vesicles (EVs),” Extracellular Vesicles and Circulating Nucleic Acids2, no. 1 (2021): 80-103.

[9] B. M. De Taeye, T. Novitskaya, O. P. McGuinness, et al., “Macrophage TNF-α Contributes to Insulin Resistance and Hepatic Steatosis in Diet-Induced Obesity,” American Journal of Physiology, Endocrinology and Metabolism293 (2007): E713-E725.

[10] P. Li, S. Liu, M. Lu, et al., “Hematopoietic-Derived Galectin-3 Causes Cellular and Systemic Insulin Resistance,” Cell167 (2016): 973-984.

[11] W. Ying, M. Riopel, G. Bandyopadhyay, et al., “Adipose Tissue Macrophage-Derived Exosomal miRNAs Can Modulate In Vivo and In Vitro Insulin Sensitivity,” Cell171 (2017): 372-384.

[12] Y. S. Forte, M. Renovato-Martins, and C. Barja-Fidalgo, “Cellular and Molecular Mechanisms Associating Obesity to Bone Loss,” Cells12 (2023): 521.

[13] B. M. Everett, M. Y. Donath, A. D. Pradhan, et al., “Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes,” Journal of the American College of Cardiology71 (2018): 2392-2401.

[14] Y. Kataria, C. Ellervik, and T. Mandrup-Poulsen, “Treatment of Type 2 Diabetes by Targeting Interleukin-1: A Meta-Analysis of 2921 Patients,” Seminars in Immunopathology41 (2019): 413-425.

[15] D. Li, J. Zhong, Q. Zhang, and J. Zhang, “Effects of Anti-Inflammatory Therapies on Glycemic Control in Type 2 Diabetes Mellitus,” Frontiers in Immunology14 (2023): 1125116.

[16] R. Shah, T. Patel, and J. E. Freedman, “Circulating Extracellular Vesicles in Human Disease,” New England Journal of Medicine379 (2018): 958-966.

[17] J. M. Pitt, G. Kroemer, and L. Zitvogel, “Extracellular Vesicles: Masters of Intercellular Communication and Potential Clinical Interventions,” Journal of Clinical Investigation126 (2016): 1139-1143.

[18] H. Ruan, Y. Li, D. Zheng, et al., “Engineered Extracellular Vesicles for Ischemic Stroke Treatment,” Innovation4 (2023): 100394.

[19] Y. Huang, T. Arab, A. E. Russell, et al., “Toward a human Brain Extracellular Vesicle Atlas: Characteristics of Extracellular Vesicles From Different Brain Regions, Including Small RNA and Protein Profiles,” Interdisciplinary Medical1 (2023): e20230016.

[20] S. L. Gaytan, E. Beaven, S. S. Gadad, and M. Nurunnabi, “Progress and Prospect of Nanotechnology for Cardiac Fibrosis Treatment,” Interdisciplinary Medical1 (2023): e20230018.

[21] S. Lee, C. Zhang, M. Kilicarslan, et al., “Integrated Network Analysis Reveals an Association Between Plasma Mannose Levels and Insulin Resistance,” Cell Metabolism24 (2016): 172-184.

[22] A. Mardinoglu, A. Stancakova, L. A. Lotta, et al., “Plasma Mannose Levels are Associated With Incident Type 2 Diabetes and Cardiovascular Disease,” Cell Metabolism26 (2017): 281-283.

[23] J. R. Etchison and H. H. Freeze, “Enzymatic Assay of D-Mannose in Serum,” Clinical Chemistry43 (1997): 533-538.

[24] G. Alton, M. Hasilik, R. Niehues, et al., “Direct Utilization of Mannose for Mammalian Glycoprotein Biosynthesis,” Glycobiology8 (1998): 285-295.

[25] V. Sharma, M. Ichikawa, and H. H. Freeze, “Mannose Metabolism: More Than Meets the Eye,” Biochemical and Biophysical Research Communications453 (2014): 220-228.

[26] M. Girard, C. Douillard, D. Debray, et al., “Long Term Outcome of MPI-CDG Patients on D-Mannose Therapy,” Journal of Inherited Metabolic Disease43 (2020): 1360-1369.

[27] B. Kranjcec, D. Papes, and S. Altarac, “D-Mannose Powder for Prophylaxis of Recurrent Urinary Tract Infections in Women: A Randomized Clinical Trial,” World Journal of Urology32 (2014): 79-84.

[28] D. Zhang, C. Chia, X. Jiao, et al., “D-Mannose Induces Regulatory T Cells and Suppresses Immunopathology,” Nature Medicine23 (2017): 1036-1045.

[29] S. Torretta, A. Scagliola, L. Ricci, et al., “D-Mannose Suppresses Macrophage IL-1β Production,” Nature Communications11 (2020): 6343.

[30] V. Sharma, J. Smolin, J. Nayak, et al., “Mannose Alters Gut Microbiome, Prevents Diet-Induced Obesity, and Improves Host Metabolism,” Cell Reports24 (2018): 3087-3098.

[31] M. Hu, Y. Chen, F. Deng, et al., “D-Mannose Regulates Hepatocyte Lipid Metabolism via PI3K/Akt/mTOR Signaling Pathway and Ameliorates Hepatic Steatosis in Alcoholic Liver Disease,” Frontiers in Immunology13 (2022): 877650.

[32] V. Vrablova, N. Kosutova, A. Blsakova, et al., “Glycosylation in Extracellular Vesicles: Isolation, Characterization, Composition, Analysis and Clinical Applications,” Biotechnology Advances67 (2023): 108196.

[33] N. Zhao, Y. F. Gao, L. Bao, et al., “Glycemic Control by Umbilical Cord-Derived Mesenchymal Stem Cells Promotes Effects of Fasting-Mimicking Diet on Type 2 Diabetic Mice,” Stem Cell Research & Therapy12 (2021): 395.

[34] L. B. Monteiro, J. S. Prodonoff, C. Favero de Aguiar, et al., “Leptin Signaling Suppression in Macrophages Improves Immunometabolic Outcomes in Obesity,” Diabetes71 (2022): 1546-1561.

[35] Z. Guo, H. Yang, J. R. Zhang, W. Zeng, and X. Hu, “Leptin Receptor Signaling Sustains Metabolic Fitness of Alveolar Macrophages to Attenuate Pulmonary Inflammation,” Science Advances8 (2022): eabo3064.

[36] C. Giordano, L. Gelsomino, I. Barone, et al., “Leptin Modulates Exosome Biogenesis in Breast Cancer Cells: An Additional Mechanism in Cell-to-Cell Communication,” Journal of Clinical Medicine8, no. 7 (2019): 1027.

[37] J. A. Davis and H. H. Freeze, “Studies of Mannose Metabolism and Effects of Long-Term Mannose Ingestion in the Mouse,” Biochimica Et Biophysica Acta1528 (2001): 116-126.

[38] L. F. Wang, G. Q. Yang, S. Yang, et al., “Alteration of Factors Associated With Hepatic Gluconeogenesis in Response to Acute Lipopolysaccharide in Dairy Goat,” Journal of Animal Science93 (2015): 2767-2777.

[39] A. C. Gomes, C. Hoffmann, and J. F. Mota, “The Human Gut Microbiota: Metabolism and Perspective in Obesity,” Gut Microbes9 (2018): 308.

[40] H. J. P. van der Zande, D. Nitsche, L. Schlautmann, B. Guigas, and S. Burgdorf, “The Mannose Receptor: From Endocytic Receptor and Biomarker to Regulator of (Meta)Inflammation,” Frontiers in Immunology12 (2021): 765034.

[41] X. Song, Q. Huang, Y. Yang, et al., “Efficient Therapy of Inflammatory Bowel Disease (IBD) With Highly Specific and Durable Targeted Ta₂C Modified With Chondroitin Sulfate (TACS),” Advanced Materials35 (2023): e2301585.

[42] B. Yu, J. Liu, J. Cheng, et al., “A Static Magnetic Field Improves Iron Metabolism and Prevents High-Fat-Diet/Streptozocin-Induced Diabetes,” Innovation2 (2021): 100077.

[43] Y. Cao, J. Y. Qiu, D. Chen, et al., “Isolation and Analysis of Traceable and Functionalized Extracellular Vesicles from the Plasma and Solid Tissues,” Journal of Visualized Experiments: JoVE (2022).

[44] V. S. Peche, T. A. Pietka, M. Jacome-Sosa, et al., “Endothelial Cell CD36 Regulates Membrane Ceramide Formation, Exosome Fatty Acid Transfer and Circulating Fatty Acid Levels,” Nature Communications14 (2023): 4029.

[45] H. Wu, W. Zhang, and W. Mu, “Recent Studies on the Biological Production of D-Mannose,” Applied Microbiology and Biotechnology103 (2019): 8753-8761.

[46] I. Huang-Doran, C. Y. Zhang, and A. Vidal-Puig, “Extracellular Vesicles: Novel Mediators of Cell Communication in Metabolic Disease,” Trends in Endocrinology and Metabolism28 (2017): 3-18.

[47] Y. Xiao, L. Zheng, X. Zou, J. Wang, J. Zhong, and T. Zhong, “Extracellular Vesicles in Type 2 Diabetes Mellitus: Key Roles in Pathogenesis, Complications, and Therapy,” Journal of Extracellular Vesicles8 (2019): 1625677.

[48] J. Liu, Y. Zhang, Y. Tian, W. Huang, N. Tong, and X. Fu, “Integrative Biology of Extracellular Vesicles in Diabetes Mellitus and Diabetic Complications,” Theranostics12 (2022): 1342-1372.

[49] Z. Ding, Z. F. Greenberg, M. F. Serafim, et al., “Understanding Molecular Characteristics of Extracellular Vesicles Derived From Different Types of Mesenchymal Stem Cells for Therapeutic Translation,” Extracellular Vesicle3 (2024): 100034.

[50] A. R. Haltom, W. E. Hassen, J. Hensel, et al., “Engineered Exosomes Targeting MYC Reverse the Proneural-Mesenchymal Transition and Extend Survival of Glioblastoma,” Extracellular Vesicle1 (2022): 100014.

[51] W. Ying, H. Gao, F. C. G. Dos Reis, et al., “MiR-690, an Exosomal-Derived miRNA From M2-Polarized Macrophages, Improves Insulin Sensitivity in Obese Mice,” Cell Metabolism33 (2021): 781-790.e5.

[52] C. Zheng, B. Sui, X. Zhang, et al., “Apoptotic Vesicles Restore Liver Macrophage Homeostasis to Counteract Type 2 Diabetes,” Journal of Extracellular Vesicles10 (2021): e12109.

[53] W. Tu, X. Hu, R. Wan, et al., “Effective Delivery of miR-511-3p With Mannose-decorated Exosomes With RNA Nanoparticles Confers Protection Against Asthma,” Journal of Controlled Release365 (2023): 602-616.

[54] S. J. Hoosdally, E. J. Andress, C. Wooding, C. A. Martin, and K. J. Linton, “The Human Scavenger Receptor CD36,” Journal of Biological Chemistry284 (2009): 16277-16288.

[55] Y. Zheng, Y. Han, Q. Sun, and Z. Li, “Harnessing Anti-Tumor and Tumor-Tropism Functions of Macrophages via Nanotechnology for Tumor Immunotherapy,” Exploration (Beijing)2 (2022): 20210166.

[56] X. Deng, J. Wang, S. Yu, et al., “Advances in the Treatment of Atherosclerosis With Ligand-Modified Nanocarriers,” Exploration4 (2024): 20230090.

[57] S. Tacconi, F. Vari, C. Sbarigia, et al., “M1-Derived Extracellular Vesicles Polarize Recipient Macrophages Into M2-Like Macrophages and Alter Skeletal Muscle Homeostasis in a Hyper-Glucose Environment,” Cell Communication and Signaling22 (2024): 193.

[58] X. Wang, S. Chen, J. He, et al., “Histone Methyltransferases G9a Mediated Lipid-Induced M1 Macrophage Polarization Through Negatively Regulating CD36,” Metabolism114 (2021): 154404.

[59] C. Bleriot, E. Barreby, G. Dunsmore, et al., “A Subset of Kupffer Cells Regulates Metabolism Through the Expression of CD36,” Immunity54 (2021): 2101-2116.e6.

[60] I. Lingvay, P. Sumithran, R. V. Cohen, and C. W. le Roux, “Obesity Management as a Primary Treatment Goal for Type 2 Diabetes: Time to Reframe the Conversation,” Lancet399 (2022): 394-405.

[61] Y. Sun, M. Asnicar, P. K. Saha, L. Chan, and R. G. Smith, “Ablation of Ghrelin Improves the Diabetic But Not Obese Phenotype of Ob/Ob Mice,” Cell Metabolism3 (2006): 379-386.

[62] N. Sainz, J. Barrenetxe, M. J. Moreno-Aliaga, and J. A. Martinez, “Leptin Resistance and Diet-Induced Obesity: Central and Peripheral Actions of Leptin,” Metabolism64 (2015): 35-46.

RIGHTS & PERMISSIONS

2025 The Author(s). Exploration published by Henan University and John Wiley & Sons Australia, Ltd.